[Rockville, MD, April 2025] A promising new therapeutic is being developed to address the urgent need for effective treatments for
IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in
IBT Vaccines, a wholly owned subsidiary of Integrated Biotherapeutics Inc., announces it has received $3.9 million to advance the development
4 November 2019 INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019 Integrated
CARB-X global partnership headed toward developing an innovative vaccine against potentially deadly Staphylococcus aureus bacteria that could be a “game
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the
Subscribe to the IBT Bioservices Tech Talk list and receive periodic updates on industry news and IBT Bioservices products and services.
For Product Information,
Orders & Technical Support
products@integratedbiotherapeutics.com
For Services
services@ibtbioservices.com
